Month: September 2026

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nearly six in ten (57%) Americans who seek money advice from chatbots would act on its guidance without checking it, according to PensionBee.

The survey of 1,000 US adults who use AI chatbots for personal finance suggests this includes decisions that are hard to undo, like how to invest or when to retire. Nearly one in four (23%) say a chatbot has already given them wrong information about their money, and 5% found out only after they had acted on it.

Click here for more information: https://www.pensionbee.com/us/research-and-insights/2026-ai-and-your-money-report

Older Americans are the least likely to think they’ve been misled. 82% of Baby Boomers who use AI for financial questions say a chatbot has never given them information that was wrong or unsuitable, the highest share of any generation.

Independent research has found AI search tools incorrectly cite or attribute news sources more than 60% of the time. Sharper questions tend to produce better answers, but knowing what to ask depends on financial literacy, which has fallen to a record low in the US.

Which financial decisions are Americans handing to AI?

Higher stakes decisions, meaning ones that may not be reversible.

• 18% would go ahead with an investment allocation the chatbot suggested.
• 16% would go ahead with a major purchase.
• 15% would go ahead with a retirement age the chatbot suggested.

Lower stakes decisions, meaning ones that carry limited cost.

• 35% would go ahead with how much to save each month.
• 26% would go ahead with canceling certain subscriptions.
• 22% would go ahead with paying off debts in a certain order.

Despite 53% of chatbot users reporting “moderate or extreme” privacy concerns, many still trade personal details for a better answer:

• 32% shared monthly spending or budget details.
• 29% shared income or salary.
• 17% shared account balances.
• 8% shared bank or credit card statements, uploaded or pasted.
• 4% shared account numbers or credit card numbers.
• 3% shared a passport number, driver’s license number, or Social Security number.

Younger generations are more likely to trust AI with personal information than older users and more likely to feel comfortable letting it act without checking the outcome. 66% of Gen Z would let AI act autonomously on their behalf, compared to 62% of Millennials, 56% of Gen X, and 47% of Baby Boomers.

“AI expands access to financial knowledge and that can be a genuine gain,” said Romi Savova, CEO of PensionBee. “But it is not without risk. A chatbot may give you one clean answer to a nuanced question, whether or not it fits your life. Retirement decisions are harder to take back, so they deserve a second look before you act.”

Methodology:

This survey was conducted online among 1,000 U.S. adults aged 18 and older, all of whom self-reported using an AI chatbot for help with their personal finances. All figures, unless otherwise stated, are from Attest. Fieldwork ran July 18–21, 2026. The sample was non-probability-based and employed demographic quotas for age, gender, and region.

Voluntary Participation: Participation in the survey was voluntary. Respondents were free to decline participation or skip any questions they chose not to answer. Participants were not required to be PensionBee clients to participate.

About PensionBee

PensionBee (LON:PBEE; OTCQX:PBNYF) is a leading retirement savings provider, helping people easily consolidate, manage, and take control of their retirement savings. The company manages over $11 billion in assets and serves nearly 330,000 customers globally, with a focus on simplicity, transparency, and accessibility. PensionBee offers Traditional, Roth, SEP, and Safe Harbor IRAs with ETF-backed portfolios. PensionBee is publicly traded on the London Stock Exchange (PBEE) with U.S. shares available on OTCQX (PBNYF).

Media Contact:
Adela McVicar
SR PR Manager, PensionBee
adela.mcvicar@pensionbee.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3bf076c3-91f7-4258-81fe-468a63db1981

^{PensionBee Inc. is registered with the Securities and Exchange Commission as an investment adviser. We do not provide in-person advice. PensionBee Inc (Delaware Registration Number SR20241105406 ) is located on 85 Broad Street, New York, New York, 10004.}

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	NextEnergy Solar Fund Ltd
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	16/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	Ordinary NPV
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	5,847,559	1.01%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	5,847,559	1.01%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
Ordinary NPV	Sale	12,500	49.5384p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
Ordinary NPV

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	17/09/2026
Contact name:	Hannah Collins – Compliance Department
Telephone number:	0151 243 7103

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

At Angry Orchard Video in New York City, fans can step inside a nostalgic video store featuring hard cider tastings, themed merchandise, iconic photo moments and a special appearance from original Ghost Face Skeet Ulrich.

Walden, N.Y., Sept. 17, 2026 (GLOBE NEWSWIRE) — This October, the nation’s No. 1 hard cider brand[1] is opening the doors to Angry Orchard Video, an immersive pop-up experience inspired by its new Thriller Variety Pack and the iconic world of Scream. In collaboration with the Scream franchise and Fun World, owner of the Ghost Face copyright and trademark, Angry Orchard will transform a downtown Manhattan space into a nostalgic, ’90s-inspired video store in celebration of the 30th anniversary of the original Scream film, bringing back the thrill of picking out your favorite scary movie, only this time with a hard cider in hand.

On Oct. 2-3, guests 21 and older who visit Angry Orchard Video will receive a customizable membership card featuring their photo to guide them through the experience. As they browse the store, fans can enjoy hard cider tastings, exclusive merchandise, photo opportunities and other experiences inspired by iconic moments from Scream.

Skeet Ulrich, whose portrayal of Billy Loomis helped make Scream a horror classic, will make a special appearance at Angry Orchard Video to celebrate the launch of Mystery Caller, the new Ghost Face-inspired cider featured in Angry Orchard’s Thriller Variety Pack.

“Part of the magic of Scream was the time it came from, when going to the video store was part of the experience,” said Ulrich. “It’s been incredible to see how different generations continue to connect with the franchise, and Angry Orchard Video brings fans back to that era while giving them a chance to step into the world of Scream in a completely new way.”

Available nationwide, Angry Orchard’s new Scream collaboration includes the Thriller Variety Pack, featuring glow-in-the-dark packaging that reveals Ghost Face and the franchise’s iconic line, “What’s your favorite scary movie?” Fans can also find limited-edition Scream-inspired Crisp Apple and Crisp Imperial single-serve cans.

The Thriller Variety Pack includes four seasonal flavors:

• NEW! Mystery Caller: As elusive as it is refreshing, Mystery Caller will leave drinkers guessing the exact blend of its scream-worthy ingredients…because you never truly know what’s behind Ghost Face’s mask.
• NEW! Caramel Apple Curse: Refreshing and indulgent, this all-new flavor combines buttery salted caramel with tart orchard apple.
• Blood Orange: Packed with juicy apple and honeysuckle notes, it slices through ordinary orange flavor to deliver a bolder, zesty sweetness with a blood-red hue.
• Headless Pumpkin: Crisp apples meet vibrant pumpkin flavor, hints of vanilla ice cream and crumbly pie crust in this nostalgic blend that rivals your grandmother’s pie.

“Scream is incredibly nostalgic for so many fans, and as we celebrate the 30th anniversary of the franchise, we wanted to bring that ‘90s nostalgia to every part of this collaboration,” said John Dorman, director of marketing at Angry Orchard. “From the VHS-inspired artwork on the Thriller Variety Pack to Angry Orchard Video, we’re bringing fans back to a time when picking out your next scary movie was just as memorable as watching it.”

To reserve a spot and learn more about Angry Orchard Video, please visit our page on Eventbrite. Space is limited.

For more information on where to find Angry Orchard, please visit angryorchard.com. Follow along @AngryOrchard on Facebook, X and Instagram. 

About Angry Orchard®
The leading hard cider across the country¹, Angry Orchard’s cider makers experiment with apple varieties near and far to continuously develop new cider styles and flavors. Crafted with real apples and the highest quality ingredients, Angry Orchard is balanced, refreshing, and full of flavor, with a wide variety of styles fit for all. At the home of Angry Orchard on a 60-acre apple orchard in New York’s Hudson Valley, the team of cider makers create small-batch experimentation with fruit grown right on-site while offering an experience for guests to sip cider amongst the trees. To learn more about Angry Orchard, visit AngryOrchard.com. Please drink responsibly.

About Paramount Products & Experiences 
Paramount Products & Experiences oversees all licensing, merchandising, and location-based experiences for Paramount, a Skydance Corporation (Nasdaq: PSKY), a leading next generation global media and entertainment company. The division brings to life iconic franchises and beloved characters through innovative products and immersive experiences across categories including toys, apparel, publishing, food and beverage, theme parks, hotels, cruises, attractions, and live entertainment. Its global portfolio is powered by content from brands such as Nickelodeon, Paramount Pictures, CBS, MTV, Comedy Central, and Paramount+, and fan-favorite franchises like PAW Patrol, SpongeBob SquarePants, Teenage Mutant Ninja Turtles, Star Trek and Yellowstone. To explore our range of consumer products and Paramount-branded merchandise, visit ParamountShop.com.

About Fun World
Fun World has been a leader in the Halloween and Easter industry since 1963, serving retailers around the globe with costumes, masks and décor as well as involvement with the entertainment and licensing projects with the world’s most recognizable mask Ghost Face®.

###

---

[1]Source: Nielsen Total US xAOC + Liquor Open State + Conv L52 W/E 6/27/26

Attachment

• Angry Orchard® Hard Cider and Scream Bring the Video Store Era Back to Life With a Scream-Inspired Pop-Up Experience

CONTACT: Rachel Kastil
Golin Ketchum
9737479399
rachel.kastil@omc.com

Concentrix commissions Everest Group to study driving AI value from transforming operating models, not simply automating work

NEWARK, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced findings of an independent market study, conducted by industry analyst firm, Everest Group. The report explores the operating models that successful businesses will use to orchestrate people, AI, data, and technology to deliver better business and customer outcomes.

Reinvent or Evolve: Intelligent Operating Models Shaping AI-Enabled Customer Journeys, discusses that while many enterprises have adopted AI, most could achieve better outcomes by maximizing AI as a key enabler of a broader operating strategy.

This report demonstrates that organizations need to redesign their operating model purposely for AI, with two core paths to maximize competitive advantage: Evolution, where AI makes human-led operations smarter and more efficient through human & AI collaboration, and Reinvention, which sees a wholesale redesign around a native AI and agentic operating environment. Currently, only about 16% of enterprises expect AI to autonomously lead most customer interactions next year.

Based on research independently conducted across enterprise decision-makers, the report finds the biggest barrier to AI success isn’t the AI itself, it’s the ability to establish governance, and orchestrate execution across functions, technologies, and teams at scale.

“The conversation around AI often focuses on technology adoption, but the bigger challenge is operating model transformation,” said Sharang Sharma, Vice President, Everest Group. “As enterprises move toward AI-enabled customer journeys, they need partners that can create a clear framework for governance, accountability and execution. Success will depend less on deploying AI tools and more on creating the organizational readiness to scale them effectively across the business.”

“The biggest opportunity organizations have with AI isn’t to automate what’s already there. It’s to create entirely new ways of delivering value,” said Chris Caldwell, President & CEO of Concentrix. “The organizations seeing the strongest results are redesigning customer experiences, embedding AI into the flow of work, and combining human expertise with intelligent technology to achieve better business outcomes. That’s where the next generation of competitive advantage will emerge.”

The report found that organizations are moving beyond AI as a standalone tool, to reshaping customer experiences through operating model redesign. For example, a leading retailer was able to deliver responses 31% faster with Agentic AI, creating a scalable path to lower cost-to-serve.

As AI moves from experimentation to enterprise scale, businesses need partners that can orchestrate strategy, consulting, technology, and operations into a united ecosystem. Through its proprietary iX Suite, Concentrix helps clients unite people, technology, data, and operations to evolve existing journeys and enable AI-native experiences.

To learn more about the study and its findings, visit Reinvent or Evolve: Intelligent Operating Models Shaping AI-Enabled Customer Journeys.

About Everest Group
Everest Group is a leading research firm helping business leaders make confident decisions. The firm’s research and advisory services help organizations navigate market challenges, strengthen business performance, and drive transformative outcomes across technology, business processes, engineering, talent, sustainability, and sourcing.

About us: Powering a World That Works  
Concentrix (NASDAQ: CNXC), is the Fortune 500® technology and services company, helping the world’s best brands create intelligent operations that perform in the real world. We design, build, and run integrated human and AI solutions, harnessing the insight from billions of real-world interactions to help 2000+ of the world’s most complex organizations solve their toughest business challenges. Backed by 20+ years of operational experience and battle tested AI, we’re the intelligent transformation partner that helps clients across every major industry move from ambition to measurable, scalable performance. Virtually everywhere. Visit concentrix.com to learn more. 

Media Contact:
Marketing & Communications
Concentrix Corporation
media@concentrix.com

From Fortune. ©2026 Fortune Media (USA) Corporation. All rights reserved. Used under license.  Fortune and Fortune 500 are registered trademarks of Fortune Media (USA) Corporation and are used under license.  Fortune and Fortune Media (USA) Corporation are not affiliated with, and do not endorse products or services of, Concentrix.

Safe Harbor Statement
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the company’s capabilities and positioning to deliver business outcomes and solve challenges for its clients, and statements that include words such as believe, expect, may, will, provide, could and should and other similar expressions. These forward-looking statements are inherently uncertain and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the company’s ability to successfully execute its strategy, competitive conditions in the company’s industry, and other factors contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2025 filed with the Securities and Exchange Commission and subsequent SEC filings. We do not undertake a duty to update forward-looking statements, which speak only as of the date on which they are made.

Copyright 2026 Concentrix Corporation and its subsidiaries. All rights reserved. Concentrix, the Concentrix logo, and all other Concentrix company, product and services names and slogans are trademarks or registered trademarks of Concentrix Corporation and its subsidiaries.

FALLS CHURCH, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) announced today that its third quarter 2026 financial results will be released on Tuesday, October 20, 2026, prior to the market opening. The earnings announcement, and accompanying earnings presentation, will be available on the company’s website at http://investor.northropgrumman.com.

Earnings Call Webcast

The company will host a live, audio only, earnings call webcast at 9:30 a.m. ET the same day. This webcast can be accessed on the company’s website at http://investor.northropgrumman.com. A replay of the webcast will be available shortly after the call and will remain available for a limited time.

About Northrop Grumman
Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

Contact: newsbureau@ngc.com

Randy Sinclair (Investors) 
randy.sinclair@ngc.com

Appointment strengthens GYG’s leadership as the Company expands GameGolf and Altus Sports Group, building a broader sports technology ecosystem

PALO ALTO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Game Your Game, Inc. (Nasdaq: GYGY) (“GYG” or the “Company”), an AI-powered sports performance technology company, today announced the appointment of Mujtaba Elgoodah as a Strategic Advisor.

The appointment comes as the Company accelerates its growth strategy across two complementary businesses: GameGolf, its AI-powered golf technology platform, and Altus Sports Group (“ASG”), its majority-owned subsidiary focused on talent representation, athlete branding and sports marketing. Elgoodah will serve the Company and ASG in a non-executive, advisory capacity.

Elgoodah brings nearly a decade of experience at the intersection of sports, technology, media and investment. He has worked with leading sports organizations and executives, including the National Basketball Players Association, where he serves as an advisor to the Executive Director. He previously spent five years with the Golden State Warriors, including the team’s 2022 NBA championship season.

Elgoodah is also an investor and advisor across a range of sports and technology ventures, including investments and strategic roles with The Bay Golf Club, Oakland Roots Sports Club and Caledonian Braves Football Club.

“Mujtaba brings a perspective that is particularly valuable to us as we expand ASG,” said Soumya Das, Chairman and CEO of GYG. “He understands the sports business from the athlete, team, league, media and investment perspectives. That combination can help us identify partnerships and opportunities that extend well beyond golf.”

Mujtaba Elgoodah said, “Sports is undergoing a fundamental transformation as technology changes how athletes perform, fans engage and businesses create value. Game Your Game is building a compelling platform across both golf and the broader sports ecosystem, and I am excited to help the team pursue those opportunities.”

About Game Your Game, Inc.

Game Your Game, Inc. (Nasdaq: GYGY) is an AI-powered sports performance technology company. The Company develops and markets the GameGolf KZN AI™ platform — an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. The platform leverages advanced GPS tracking, embedded neural network technology, and AI-powered analytics to provide golfers of all skill levels with real-time insights, on-course strategy recommendations, and personalized performance data. Game Your Game’s technology has been adopted by golfers in more than 140 countries, with over 36,000 golf courses mapped and an estimated number of more than 300 million shots tracked across the lifetime of its platforms. The Company is headquartered in Palo Alto, California. For more information, visit www.gameyourgame.com.

About Altus Sports Group, Inc.

Altus Sports Group, Inc., a majority-owned subsidiary of Game Your Game, Inc., was formed in August 2026 to build a connected platform for the sports business across talent representation, athlete branding and sports marketing. For more information, visit www.altus-sports.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause the Company’s or ASG’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s growth strategy, the expansion of GameGolf and ASG, the development of a broader sports technology ecosystem, and the anticipated contributions of Mujtaba Elgoodah to the Company and ASG. These statements are only predictions and involve known and unknown risks and uncertainties, including, but not limited to, the Company’s ability to expand beyond performance tracking products and offerings; the Company’s ability to retain the services of, and realize the anticipated benefits from, its strategic advisors; the Company’s ability to develop ASG’s business and realize the anticipated benefits therefrom; the ability of ASG to attract and retain talent agents, clients and key personnel, including ASG’s founding team; the ability of ASG to identify, negotiate, finance and complete any acquisitions, investments or partnerships on acceptable terms or at all; ASG’s ability to effectively compete in the sports representation and marketing industries; ASG’s ability to comply with regulatory and league rules applicable to talent representation; ASG’s ability to attract athletes to participate in its platform through the engagement of talent agents and sports marketers; and other factors identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s Registration Statement on Form S-1 (File No. 333-296763), as amended, which was declared effective by the SEC on July 28, 2026, and the prospectus forming a part thereof, [the Company’s Registration Statement on Form S-1 filed with the SEC on August 21, 2026, as amended,] and other periodic and current reports filed with the SEC from time to time, which are available at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, you should not place undue reliance on forward-looking statements as a prediction of actual results. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release, except as required by law.

Investor and Media Contact
KCSA Strategic Communications
Phil Carlson, Managing Director
GYGY@KCSA.com

New Filing Seeks Broad Protection Around Creative Medical’s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency, Manufacturing Controls and Additional Therapeutic Applications

PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company’s proprietary cell-free regenerative medicine platform.

The newly filed application builds upon Creative Medical’s existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.

The filing is intended to strengthen the Company’s long-term intellectual property position as Creative Medical advances Ultrasome beyond its initial osteoarthritis program and evaluates the platform’s potential across additional areas of regenerative medicine.

“As our understanding of the Ultrasome platform continues to advance, we believe it is important to protect not only its therapeutic applications, but also the underlying product characteristics, biological activity and manufacturing framework that distinguish the platform,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “This filing represents another step in building a broad intellectual property estate around what we believe can become a highly scalable cell-free regenerative medicine platform.”

Building Intellectual Property Around Product Function, Not Simply Particle Identity

Creative Medical’s development strategy for Ultrasome incorporates both physical product characterization and biologically relevant functional testing designed to evaluate activity associated with tissue protection and regenerative signaling.

The newly filed provisional patent application seeks intellectual property protection around multiple aspects of this approach, including methods intended to characterize the biological activity and consistency of manufactured product.

Management believes that integrating product composition, functional potency and manufacturing control may provide important differentiation as the field of extracellular-vesicle and secretome-based therapeutics continues to evolve.

The patent application also includes intellectual property directed toward methods for evaluating changes in product biological activity that may not be reflected by particle measurements alone.

“A central component of our development strategy is establishing reproducible biological activity across manufactured product,” Warbington added. “We believe that connecting manufacturing, product characterization and functional performance is important both scientifically and strategically as we advance this platform.”

Builds on Previously Announced Ultrasome™ Knee Osteoarthritis Program

The new patent filing follows Creative Medical’s previously announced pilot study evaluating Ultrasome in patients with knee osteoarthritis.

As announced in April 2026, the study reported that approximately 93% of participants demonstrated clinically meaningful improvements in mobility and pain, and no serious adverse events were reported.

The Company continues to view osteoarthritis as an important initial application for Ultrasome while exploring the broader potential of the platform across regenerative medicine.

The new provisional filing includes intellectual property intended to preserve development flexibility for musculoskeletal and cartilage disorders as well as selected clinical applications. These additional applications remain in various stages of research and development and should not be interpreted as evidence of clinical efficacy or regulatory approval in those indications.

Extending a GMP-Based Regenerative Medicine Platform

Ultrasome is being developed from Creative Medical’s proprietary Olastrocel™ regenerative medicine platform.

The underlying cellular source is derived from an independently validated Good Manufacturing Practice master cell bank, with manufacturing and quality information maintained within a U.S. Food and Drug Administration Drug Master File.

A Drug Master File is a confidential regulatory submission containing manufacturing and quality information and does not itself constitute FDA approval, clearance or authorization of a therapeutic product.

Creative Medical believes the ability to leverage a controlled cellular starting material across both cell-based and cell-free programs may support future manufacturing scalability, product consistency and expansion of its regenerative medicine pipeline.

Expanding Creative Medical’s Intellectual Property Portfolio

The new application is part of Creative Medical’s strategy of building intellectual property protection around multiple layers of its regenerative medicine technologies, including:

• proprietary cell-free compositions;
• functional biological characteristics;
• manufacturing and quality-control methodologies;
• stability and product-release approaches;
• targeted delivery methods; and
• therapeutic applications across selected regenerative medicine indications.

As a provisional patent application, the filing establishes an initial U.S. priority date for the disclosed subject matter and provides the Company with the opportunity to pursue U.S. and international patent protection through subsequent filings.

The provisional application has not been examined by the U.S. Patent and Trademark Office, and there can be no assurance regarding the scope or issuance of any future patent claims.

Strategic Focus

Creative Medical intends to continue advancing its intellectual property portfolio in parallel with its clinical and translational development programs.

Management believes a combination of clinical development, proprietary manufacturing, functional product characterization and intellectual property protection may create multiple opportunities for future platform development, strategic collaboration and value creation.

“Our goal is to build durable value around the science,” Warbington concluded. “We believe the combination of our clinical-stage regenerative platform, expanding cell-free programs and growing intellectual property portfolio positions Creative Medical to pursue multiple high-value opportunities while maintaining disciplined development of our core programs.”

About Ultrasome™

Ultrasome™ is Creative Medical Technology Holdings’ proprietary cell-free regenerative medicine platform derived from the Company’s umbilical cord tissue technology. The platform is being developed to deliver biologically active regenerative signals through scalable, off-the-shelf formulations for potential use across selected degenerative and regenerative medicine applications.

Ultrasome’s initial clinical development has focused on osteoarthritis of the knee.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a biotechnology company advancing regenerative medicine therapies derived from adult and perinatal cell technologies. The Company’s programs span multiple areas of regenerative medicine and are designed to translate proprietary cellular and cell-free technologies into therapeutic opportunities for patients with significant unmet medical needs.

For more information, please visit www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the potential scope and value of the Company’s intellectual property portfolio; the development, scalability, manufacturing, potential therapeutic applications and commercial potential of Ultrasome™; future patent prosecution and patent issuance; future clinical and translational development; potential strategic collaborations; and the Company’s plans to evaluate additional regenerative medicine indications. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, risks associated with patent prosecution and enforcement, clinical development, regulatory review, manufacturing, scientific validation, financing, market acceptance and other risks described in the Company’s filings with the Securities and Exchange Commission.

A provisional patent application is not examined by the USPTO and does not guarantee that a patent will issue or that any subsequently issued claims will provide commercially meaningful protection.

Creative Medical Technology Holdings, Inc. undertakes no obligation to update forward-looking statements except as required by applicable law.

Investor & Media Contacts

Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com

Investor Relations / The Equity Group Inc.
Devin Sullivan
devin.sullivan@theequitygroup.com Conor Rodriguez
conor.rodriguez@theequitygroup.com

DELTA, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF |FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, announces that it has invested USD 1,000,000 in convertible preferred stock of global fusion technology provider Type One Energy Group (“Type One Energy”). The transaction reflects RecycLiCo’s broad commitment to supporting technologies across the advanced energy and critical-materials ecosystem.

Type One Energy is mission-driven to provide sustainable, affordable fusion power to the world. Established in 2019 and venture-backed in 2023, the company is led by a team of globally recognized fusion scientists with a strong track record of building state-of-the-art stellarator fusion machines and veteran business leaders experienced in scaling companies and commercializing energy technologies. Type One Energy applies proven advanced manufacturing methods, modern computational physics, and high-field superconducting magnets to develop its optimized stellarator fusion energy system. Its FusionDirect™ development program pursues the lowest-risk, shortest-schedule path to a commercial fusion power plant over the coming decade, using a partner-intensive and capital-efficient strategy. Type One Energy is committed to community engagement in the development and deployment of its clean energy technology. 

“We are pleased to support Type One Energy and the advancement of its technology,” said Richard Sadowsky, Interim Chief Executive Officer, RecycLiCo. “RecycLiCo operates at the intersection of critical materials, advanced technology and the global transition to sustainable energy to which Type One’s next-generation fusion technology will be an important contributor.”

About RecycLiCo

RecycLiCo Battery Materials Inc. is a critical minerals refining company specializing in the use of advanced hydrometallurgical technologies for processing mined ore and the upcycling of lithium-ion battery materials. RecycLiCo’s processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage as well as broader industrial applications. RecycLiCo’s business focus aligns with the global demand for future-ready, responsible supply chains and the growing movement to strengthen domestic sourcing of critical materials.

For more information, please contact:
Paola Ashton
PRA Communications
Telephone: 604-681-1407
Email: pashton@pracommunications.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nasdaq announced today that it will delist the Class A Common Stock and Warrants of Abpro Holdings, Inc. Abpro Holdings, Inc’s Class A Common Stock and Warrants were suspended on February 23, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of CIMG Inc. CIMG Inc.’s common stock was suspended on March 6, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of MDJM LTD. MDJM LTD’s Class A Ordinary Shares were suspended on March 20, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of Davis Commodities Limited. Davis Commodities Limited’s Class A Ordinary Shares were suspended on March 25, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Maxeon Solar Technologies, Ltd. Maxeon Solar Technologies, Ltd.’s ordinary shares were suspended on May 1, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.’s common stock was suspended on May 5, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Aditxt, Inc. Aditxt, Inc.’s common stock was suspended on June 25, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Semilux International Ltd. Semilux International Ltd.’s ordinary shares were suspended on June 8, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of Pitanium Limited. Pitanium Limited’s Class A Ordinary Shares were suspended on July 16, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Smart Powerr Corp. Smart Powerr Corp.’s common stock was suspended on July 21, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of SPAR Group, Inc. SPAR Group, Inc.’s common stock was suspended on July 23, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Nuvve Holding Corp. Nuvve Holding Corp.’s common stock was suspended on July 24, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Common Stock of Vestand Inc. Vestand Inc.’s Class A Common Stock was suspended on July 27, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Empro Group Inc. Empro Group Inc.’s ordinary shares was suspended on July 27, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares, units, and warrants of Keen Vision Acquisition Corporation. Keen Vision Acquisition Corporation’s securities were suspended on August 3, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Nusatrip Incorporated. Nusatrip Incorporated’s common stock was suspended on August 12, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of FAST TRACK GROUP. FAST TRACK GROUP’s ordinary shares were suspended on August 18, 2026 and have not traded on Nasdaq since that time.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

BRENTWOOD, Tenn., Sept. 17, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced it has completed the previously announced sale of its ownership interests in its Idaho Falls facilities to Intermountain Health.

Under the terms of the Securities Purchase Agreements, Surgery Partners received $797 million in gross proceeds and $587 million in net cash proceeds at closing, subject to customary post-closing adjustments. The transaction includes Mountain View Hospital and Idaho Falls Community Hospital (together, referred to as Idaho Falls Facilities). Under Intermountain Health leadership, physician ownership of Mountain View Hospital will remain unchanged.

“With the completion of this important transaction, Surgery Partners enters a new chapter better positioned for long-term growth as a pure-play short-stay surgical provider,” said Eric Evans, Chief Executive Officer of Surgery Partners. “As we recently disclosed in our second quarter earnings call, our core business is delivering strong results, with same facility revenue growth driven by our continued focus on higher-acuity procedures and a differentiated operating platform. Our updated full-year 2026 outlook underscores the benefit of our portfolio optimization actions, with this transaction expected to be accretive to adjusted earnings growth on an annual basis, in addition to reducing our balance sheet leverage and improving free cash flow conversion. We are encouraged by our recent momentum and remain confident in our long-term strategy and ability to deliver sustained value for stockholders.”

Financial Highlights

• The transaction values the combined Idaho Falls Facilities at approximately $1.15 billion, with total consideration to Surgery Partners of approximately $797 million of gross proceeds and $587 million of net cash proceeds.
• Transaction proceeds represent an approximately 7x multiple based on the Idaho Falls Facilities’ last 12 months adjusted EBITDA performance (through June 30, 2026), and an approximately 17x multiple based on average distributions received from Idaho Falls over the past three years.
• Balance sheet leverage, as calculated under the Company’s credit agreement, is expected to improve by 30bps, from 4.4x at the end of Q2 2026.
• Transaction proceeds will be used primarily to pay down debt.

Operational Highlights

This transaction significantly streamlines Surgery Partners’ business and portfolio. Excluding the Idaho Falls Facilities, the Company expects:

• 50% reduction in Medicaid payor mix, with new annualized mix expected to be under 2% of revenue.
• 100% elimination of neonatology and obstetrics service lines.
• 50% reduction in intensive care beds and majority reduction in total emergency department visits.
• 75% reduction in non-surgical admissions.
• 100% elimination of inpatient pediatrics businesses.
• 100% reduction in retail and compounding pharmacy service lines.

Updated 2026 Guidance

• Full-year 2026 revenue guidance is in the range of $3.08 billion to $3.18 billion and Adjusted EBITDA guidance is at least $489 million, reflecting the removal of the Idaho Falls Facilities’ contribution for the remaining portion of the year.
• On a pro forma basis, excluding the Idaho Falls Facilities for the full-year 2026, revenue guidance is in the range of $2.60 billion to $2.67 billion and Adjusted EBITDA guidance is at least $414 million.

Advisors

Barclays served as the lead financial advisor to Surgery Partners, and McDermott Will & Schulte LLP served as its legal counsel. RBC Capital Markets, LLC served as the lead financial advisor to Intermountain Health, and Hall, Render, Killian, Heath & Lyman, P.C. served as its legal counsel.

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

About Idaho Falls Facilities

The Idaho Falls Facilities have built a long-standing reputation as preferred providers and leaders in delivering high-quality, affordable care for the Idaho Falls region. Mountain View Hospital was founded in 2002 and has grown into a leading surgical hub and Level III NICU, with the opening of the Idaho Falls Community Hospital in 2019 adding scalable acute care capabilities. Combined, the locations employ over 150 physicians and include 126 beds with a breadth of services across nine surgical specialties and a diverse range of additional service lines, including oncology, emergency department and ICU services, and neonatology.

About Intermountain Health

Headquartered in Utah with locations in six states and additional operations across the western U.S., Intermountain Health is a nonprofit system of 34 hospitals, approximately 400 clinics, medical groups with some 4,600 employed physicians and advanced care providers, a nonprofit health plan called Select Health with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements, including those regarding growth, our anticipated operating results for future periods and other similar statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects,” “forecasts,” “may,” “could,” and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, the possibility that the anticipated benefits of the sale to the Company are not realized as expected, the potential adverse effect of the announcement on the market price of, or trading in, the Company’s securities and on the Company’s business relationships, operating results, and business generally, including the ability to retain key personnel; potential litigation relating to the transaction that could be instituted against the Company or its affiliates, officers, or directors, and the effects of any outcomes related thereto; reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties identified and discussed from time to time in the Company’s reports filed with the Securities and Exchange Commission (the “SEC”), including in Item 1A under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other reports filed with the SEC. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles in the United States (“GAAP”). We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, financial measures reported in accordance with GAAP. We are not able to project components of the 2026 Adjusted EBITDA guidance and therefore cannot provide a reconciliation of the forward-looking non-GAAP financial measures.

Contact

Surgery Partners Investor Relations
(615) 234-8940
IR@surgerypartners.com